These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Jubala CM; Wojcieszyn JW; Valli VE; Getzy DM; Fosmire SP; Coffey D; Bellgrau D; Modiano JF Vet Pathol; 2005 Jul; 42(4):468-76. PubMed ID: 16006606 [TBL] [Abstract][Full Text] [Related]
3. Cloning of canine toll-like receptor 9 and its expression in dog tissues. Hashimoto M; Asahina Y; Sano J; Kano R; Moritomo T; Hasegawa A Vet Immunol Immunopathol; 2005 Jun; 106(1-2):159-63. PubMed ID: 15911003 [TBL] [Abstract][Full Text] [Related]
4. Cloning of canine Toll-like receptor 7 gene and its expression in dog tissues. Okui Y; Kano R; Maruyama H; Hasegawa A Vet Immunol Immunopathol; 2008 Jan; 121(1-2):156-60. PubMed ID: 17913244 [TBL] [Abstract][Full Text] [Related]
5. Molecular cloning and tissue expression of canine Toll-like receptor 2 (TLR2). Ishii M; Hashimoto M; Oguma K; Kano R; Moritomo T; Hasegawa A Vet Immunol Immunopathol; 2006 Mar; 110(1-2):87-95. PubMed ID: 16260044 [TBL] [Abstract][Full Text] [Related]
6. Identification of altered MicroRNA expression in canine lymphoid cell lines and cases of B- and T-Cell lymphomas. Uhl E; Krimer P; Schliekelman P; Tompkins SM; Suter S Genes Chromosomes Cancer; 2011 Nov; 50(11):950-67. PubMed ID: 21910161 [TBL] [Abstract][Full Text] [Related]
7. The cloning and expression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase 2 in normal canine lymph nodes and in canine lymphoma. Newman RG; Kitchell BE; Wallig MA; Paria B Res Vet Sci; 2008 Apr; 84(2):206-14. PubMed ID: 17604063 [TBL] [Abstract][Full Text] [Related]
8. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251 [TBL] [Abstract][Full Text] [Related]
9. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma. Rue SM; Eckelman BP; Efe JA; Bloink K; Deveraux QL; Lowery D; Nasoff M Vet Immunol Immunopathol; 2015 Apr; 164(3-4):148-59. PubMed ID: 25764941 [TBL] [Abstract][Full Text] [Related]
10. Genomic organization of the T-cell receptor gamma gene and PCR detection of its clonal rearrangement in canine T-cell lymphoma/leukemia. Yagihara H; Tamura K; Isotani M; Ono K; Washizu T; Bonkobara M Vet Immunol Immunopathol; 2007 Feb; 115(3-4):375-82. PubMed ID: 17166595 [TBL] [Abstract][Full Text] [Related]
11. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301 [TBL] [Abstract][Full Text] [Related]
12. [Construction and expression of chimeric anti-human CD20 monoclonal antibody]. Wang YG; Huang Y; Gu X; Yu M; Feng JN; Sun YX; Li Y; Shen BF Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 May; 22(3):363-7. PubMed ID: 16643801 [TBL] [Abstract][Full Text] [Related]
13. Molecular cloning and expression analysis of the canine chemokine receptor CCR9. Maeda S; Ohno K; Tsukamoto A; Nakashima K; Fukushima K; Goto-Koshino Y; Fujino Y; Tsujimoto H Vet Immunol Immunopathol; 2012 Jan; 145(1-2):534-9. PubMed ID: 22209203 [TBL] [Abstract][Full Text] [Related]
14. CFFM4: a new member of the CD20/FcepsilonRIbeta family. Gingras MC; Lapillonne H; Margolin JF Immunogenetics; 2001 Aug; 53(6):468-76. PubMed ID: 11685457 [TBL] [Abstract][Full Text] [Related]
15. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581 [TBL] [Abstract][Full Text] [Related]
16. Studies of cocktail therapy with multiple cytokines for neoplasia or infectious disease of the dog I. cDNA cloning of canine IL-3 and IL-6. Shin IS; Kim HR; Nam MJ; Youn HY J Vet Sci; 2001 Aug; 2(2):115-20. PubMed ID: 14614281 [TBL] [Abstract][Full Text] [Related]
17. Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo. Steingold SF; Sharp NJ; McGahan MC; Hughes CS; Dunn SE; Page RL Anticancer Res; 1998; 18(1A):393-400. PubMed ID: 9568108 [TBL] [Abstract][Full Text] [Related]
18. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry. Gelain ME; Mazzilli M; Riondato F; Marconato L; Comazzi S Vet Immunol Immunopathol; 2008 Feb; 121(3-4):179-88. PubMed ID: 17981339 [TBL] [Abstract][Full Text] [Related]
19. A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas. Balhorn RL; Skorupski KA; Hok S; Balhorn MC; Guerrero T; Rebhun RB Vet Immunol Immunopathol; 2010 Oct; 137(3-4):235-42. PubMed ID: 20576295 [TBL] [Abstract][Full Text] [Related]
20. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation. Impellizeri JA; Howell K; McKeever KP; Crow SE Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]